Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Relative Bioavailability and Food Effect Cohort to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of CYB003 in Healthy Participants With and Without Major Depressive Disorder (MDD)

Next Previous
Trial Profile

A Phase I/IIa, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Relative Bioavailability and Food Effect Cohort to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of CYB003 in Healthy Participants With and Without Major Depressive Disorder (MDD)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CYB 003 (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Sponsors Cybin

Most Recent Events

  • 23 Apr 2025 According to a Cybin Inc. media release, Kimball A. Johnson, served as the principal investigator in this trial.
  • 10 Dec 2024 Results presented in the Cybin Inc Media Release.
  • 10 Dec 2024 According to a Cybin Inc. media release, company announced 12-month efficacy data from phase II presented at the American College of Neuropsychopharmacology Annual Meeting taking place December 8-11, 2024, in Phoenix, Arizona.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top